Kamaleshwaran Koramadai Karuppusamy, Joseph Jephy, Kalarikal Radha Krishnan, Shinto Ajit Sugunan
Department of Nuclear Medicine and PET/CT, Comprehensive Cancer Care Center, Kovai Medical Center and Hospital Limited, Coimbatore, India.
Indian J Nucl Med. 2017 Apr-Jun;32(2):140-142. doi: 10.4103/0972-3919.202239.
Lung cancer is currently one of the most common malignancies in the world. Metastatic disease is observed in ~ 40% of patients with lung cancer, with the most common sites of metastasis being the bone, liver, brain and adrenal glands. Peritoneal carcinomatosis (PC) is defined as the progression of the primary cancer to the peritoneum. PC is a rare clinical event in lung cancer. Tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR), such as erlotinib are used for the treatment of patients with advanced non-small cell lung cancer (NSCLC). F-18 FDG PET/CT has proven capable of predicting response to therapy with erlotinib. We present a rare F-18 FDG PET/CT image findings of a 45 year old male with NSCLC with PC treated with erlotinib showing response to the treatment.
肺癌是目前全球最常见的恶性肿瘤之一。约40%的肺癌患者会出现转移，最常见的转移部位是骨骼、肝脏、脑和肾上腺。腹膜癌病（PC）定义为原发性癌症向腹膜进展。PC在肺癌中是一种罕见的临床情况。靶向表皮生长因子受体（EGFR）的酪氨酸激酶抑制剂，如厄洛替尼，用于治疗晚期非小细胞肺癌（NSCLC）患者。F-18 FDG PET/CT已被证明能够预测对厄洛替尼治疗的反应。我们展示了一名45岁接受厄洛替尼治疗的NSCLC合并PC男性患者罕见的F-18 FDG PET/CT影像表现，显示出对治疗的反应。
